Viatris Inc. logo
Viatris Inc. (VTRS)
Compare

VTRS Balance Sheet

Assets, liabilities, and equity analysis

VTRS Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Total Current Assets
10.917B10.917B9.221B9.951B9.775B9.622B9.521B11.308B11.792B
1.804B1.804B1.348B975.300M566.400M755.000M734.800M1.879B917.200M
Short-Term Investments
0.000.00106.400M181.800M242.200M247.200M355.100M169.000M225.200M
Cash & Short-Term Investments
1.804B1.804B1.454B1.157B808.600M1.002B1.090B2.048B1.142B
3.076B3.076B3.347B3.587B3.597B3.389B3.522B3.945B3.862B
3.927B3.927B3.999B4.111B4.264B4.096B3.854B4.085B3.942B
36.835B36.835B37.193B37.920B38.411B38.475B41.501B44.754B45.330B
2.528B2.528B2.885B2.892B2.919B2.901B2.919B2.945B2.936B
6.692B6.692B6.755B6.731B6.748B6.462B9.133B9.562B9.326B
Intangible Assets
14.482B14.482B15.102B15.723B16.324B16.662B17.071B17.979B18.419B
Long-Term Investments
0.000.00815.000M850.000M950.000M1.234B1.350B1.477B1.438B
Total Current Liabilities
6.810B6.810B7.094B7.364B7.133B5.720B5.779B7.512B7.709B
1.749B1.749B1.294B1.326B1.320B1.518B1.355B1.242B1.383B
1.931B1.931B2.043B1.944B1.673B700K600K1.446B2.368B
Total Liabilities
22.177B22.177B22.482B22.703B22.841B22.825B22.865B24.962B25.810B
12.414B12.414B12.481B12.488B12.792B14.178B14.039B14.303B14.731B
14.345B14.345B14.701B14.715B14.758B14.459B14.306B16.022B17.379B
Net Debt (Cash)
12.540B12.540B13.353B13.740B14.192B13.704B13.571B14.143B16.462B
14.658B14.658B14.711B15.218B15.570B15.650B18.636B19.792B19.520B
Common Stock
12.600M12.600M12.500M12.500M12.500M12.400M12.300M12.300M12.300M
-211.900M-211.900M-388.300M-48.200M80.000M227.900M3.419B4.082B4.134B
1.601.601.301.351.371.681.651.511.53
0.980.981.000.970.950.920.770.810.89

VTRS Annual Balance Sheet (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/30/2018
Total Current Assets
9.221B9.521B12.976B10.635B10.903B12.867B6.757B6.368B
1.348B734.800M991.900M1.260B701.200M844.400M475.600M388.100M
Short-Term Investments
106.400M355.100M192.500M212.600M233.800M203.500M109.100M57.500M
Cash & Short-Term Investments
1.454B1.090B1.184B1.472B935.000M1.048B584.700M449.200M
3.347B3.522B4.041B4.143B4.266B4.844B3.059B2.417B
3.999B3.854B3.470B3.519B3.978B5.472B2.671B2.580B
37.193B41.501B47.685B50.022B54.843B61.553B31.256B32.735B
2.885B2.919B3.005B3.284B3.479B3.784B2.404B2.170B
6.755B9.133B9.867B10.426B12.114B12.347B9.591B9.748B
Intangible Assets
15.102B17.071B19.181B22.607B26.134B29.683B11.650B13.665B
Long-Term Investments
815.000M1.350B1.142B1.091B81.400M47.900M92.200M138.700M
Total Current Liabilities
7.094B5.779B7.777B6.746B9.884B10.563B5.569B4.588B
1.294B1.355B1.381B1.158B1.056B1.346B1.062B1.245B
2.043B600K1.935B1.250B3.353B3.409B1.458B657.100M
Total Liabilities
22.482B22.865B27.218B28.950B34.350B38.599B19.372B20.568B
12.481B14.039B16.188B18.015B19.717B22.429B11.214B13.161B
14.701B14.306B18.371B19.528B23.358B26.161B12.924B13.818B
Net Debt (Cash)
13.353B13.571B17.379B18.268B22.657B25.317B12.449B13.430B
14.711B18.636B20.467B21.072B20.493B22.954B11.884B12.167B
Common Stock
12.500M12.300M12.200M12.100M12.100M12.100M6.100M6.000M
-388.300M3.419B4.640B5.176B3.689B5.361B6.031B6.011B
1.301.651.671.581.101.221.211.39
1.000.770.900.931.141.141.091.14

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Canonsburg, PA
32,000 employees
Healthcare / Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Scott Andrew Smith